RE:RE:RE:RE:RE:RE:RE:RE:RE:Board UpdateFelker, not that it is the reality, but yes it could be since these venture markets do not trade based on fundamentals but on emotions. But, I would welcome that based on just the existing business. $40 million valuation for a 5-year old company that has grown its revenues to above $10 million early on and has big name clients, I'll take that any day. The reason why KNR was so cheap before BioCloud is because nobody knew about it. So, the point that I am trying to make is that KNR was very cheap based on what it had compared to other venture companies before BioCloud and is not a good benchmark.